Welcome to our dedicated page for Moderna SEC filings (Ticker: MRNA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Moderna, Inc. (NASDAQ: MRNA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including current reports, proxy statements and other key documents filed with the U.S. Securities and Exchange Commission. For a commercial-stage biotechnology company focused on mRNA medicines, these filings offer detailed insight into its financial condition, governance, pipeline priorities and material agreements.
Investors can review Form 8-K current reports where Moderna describes significant events such as quarterly and semiannual financial results, new credit facilities and major business updates. For example, the company has used Form 8-K to report its entry into a $1.5 billion Credit and Guaranty Agreement, to furnish quarterly earnings press releases and to highlight pipeline and strategy updates presented at its Analyst Day.
The page also includes proxy materials such as the DEF 14A, where Moderna explains proposals submitted to shareholders, outlines compensation and incentive structures, and discusses governance matters. A recent definitive proxy statement describes a one-time stock option exchange program for non-Executive Committee employees, including its rationale, design features and potential impact on shareholders.
Through these filings, users can examine Moderna’s capital structure and liquidity arrangements, including the terms of its credit facility, guarantees by subsidiaries and financial covenants such as minimum liquidity requirements. They can also see how the company communicates its strategic priorities, cost-efficiency plans and cash breakeven targets in official documents.
Stock Titan enhances this information by organizing filings chronologically and by type, and by pairing them with AI-powered summaries that highlight the main points from lengthy documents. This helps readers quickly understand the significance of Moderna’s 8-Ks, proxy statements and other SEC reports without having to parse every page, while still allowing full access to the underlying filings for deeper analysis.
The Vanguard Group filed Amendment No. 6 to a Schedule 13G/A reporting its beneficial ownership of Moderna Inc common stock as 0 shares (0%). The filing explains an internal realignment effective January 12, 2026 that disaggregated certain Vanguard subsidiaries, and it was signed on 03/27/2026.
Moderna is asking shareholders to vote at its virtual 2026 annual meeting on five items, including electing two Class II directors, approving executive pay on an advisory basis, setting say‑on‑pay frequency to one year, and ratifying Ernst & Young as auditor for 2026.
The proxy highlights 2025 results: $1.9 billion in total revenue, about $2.2 billion in annual cost savings (a 30% reduction from 2024), and $8.1 billion in cash, cash equivalents and investments as of December 31, 2025. The company reports three regulatory approvals in infectious disease vaccines and eight Phase 2/3 oncology trials for intismeran autogene with Merck.
mNEXSPIKE became a key U.S. product, representing roughly 24% of all U.S. retail COVID vaccinations in 2025 and nearly one‑third among adults 65+. The Board approved a $1.5 billion five‑year term loan facility to add non‑dilutive capital and oversaw cost discipline, digital investments and expansion of global manufacturing sites.
The nine‑member, staggered Board includes eight independent directors, three women and multiple members with scientific and healthcare backgrounds. Executive pay is positioned as strongly performance‑linked, with 2025 corporate bonuses funded at 170% of target and at‑risk compensation at 91% of target pay for the CEO and 89% for other named executives.
Moderna, Inc. Chief Legal Officer Shannon Thyme Klinger reported equity compensation activity involving restricted stock units and common shares. On March 5, 2026, 11,797 restricted stock units were exercised into 11,797 shares of common stock at a stated price of $0.00 per share.
On the same date, 5,704 shares of common stock were disposed of at $57.80 per share to satisfy tax withholding obligations in connection with the vesting of the restricted stock units. After these transactions, Klinger directly held 65,782 shares of common stock and 129,774 restricted stock units, with the restricted stock units converting into common stock on a one-for-one basis.
Moderna, Inc. Chief Financial Officer James M. Mock reported equity compensation activity involving restricted stock units and related common stock on March 5, 2026. He acquired 11,797 shares of common stock through the exercise of restricted stock units that convert into common stock on a one-for-one basis. The filing also reports 5,704 common shares disposed of to satisfy tax withholding obligations in connection with the vesting of these restricted stock units, leaving him with 56,998 common shares held directly after the tax withholding transaction.
Moderna, Inc. entered a major settlement with Arbutus Biopharma and Genevant to resolve all worldwide patent litigation tied to Spikevax, mRESVIA and other infectious disease vaccines using SM-102 lipid nanoparticles. Moderna will pay a $950 million noncontingent lump sum by July 8, 2026.
Depending on the outcome of its appeal over the applicability of 28 U.S.C. § 1498 to certain U.S. government–supplied doses, Moderna may also owe a contingent lump sum of up to $1.3 billion, subject to proration and potential repayment with interest. In return, Moderna receives a fully paid-up, royalty-free, irrevocable worldwide license and covenant not to sue covering its infectious disease vaccine portfolio, with no future royalties owed.
Moderna, Inc. Chief Executive Officer Stephane Bancel reported receiving a grant of 250,932 stock options with an exercise price of $0.00 per share. According to the filing, 25% of this option will vest and become exercisable on March 1, 2027, with the remaining 75% vesting in twelve equal quarterly installments thereafter.
After this grant, Bancel is shown as directly holding 6,187,791 shares of Moderna common stock. The filing also reports additional common stock held indirectly through entities Boston Biotech Ventures and OCHA LLC in amounts of 9,210,686 and 6,564,880 shares, respectively, with Bancel disclaiming beneficial ownership except to the extent of any pecuniary interest.
Moderna, Inc. reported multiple equity transactions involving President Stephen Hoge. On March 1, 2026, he received a stock option covering 125,466 shares and a new award of 165,230 restricted stock units, each at an exercise or acquisition price of $0.00 per share. The new option and RSU awards begin vesting on March 1, 2027, with 25% vesting then and the remainder in twelve equal quarterly installments.
On February 27, 2026, several existing restricted stock unit awards were exercised, converting into common stock on a one-for-one basis. In connection with these vests, portions of the resulting shares were delivered at $51.71 per share to satisfy tax withholding obligations. Following these transactions, Hoge held 1,477,997 shares of common stock directly, plus additional indirect holdings of common stock by Valhalla, LLC and by a trust for his spouse and children, for which he disclaims beneficial ownership except for any pecuniary interest.
Moderna, Inc. Chief Legal Officer Shannon Thyme Klinger reported multiple equity transactions. She exercised stock options and restricted stock units that converted into common shares, then sold 13,885 common shares at $52.29 per share under a Rule 10b5-1 trading plan. Several grants of stock options and restricted stock units were also reported, and her direct common stock holdings were 59,689 shares after these transactions.
Moderna, Inc. Chief Financial Officer James M. Mock reported several equity compensation transactions. On March 1, 2026, he received a grant of 37,639 stock options and 49,569 restricted stock units (RSUs), with options and RSUs vesting 25% on March 1, 2027 and the remainder in twelve quarterly installments.
On February 27, 2026, multiple RSU awards converted into common stock on a one-for-one basis, and shares totaling 160, 375, and 4,788 were disposed of at $51.71 per share to cover tax withholding obligations. Following these transactions, Mock continued to hold common stock and derivative awards directly.